New Oral Anticoagulants in the Management of Venous Thromboembolism: A Major Advance?  by Sciascia, S. & Hunt, B.J.
Eur J Vasc Endovasc Surg (2014) 48, 487e488EDITORIALNew Oral Anticoagulants in the Management of Venous Thromboembolism:
A Major Advance?For the last 60 years, vitamin K antagonists (VKAs) have been
the only available oral anticoagulant for the primary and
secondary prevention of both arterial and venous throm-
boembolism. However, VKAs have unpredictable pharma-
cokinetics as well as complex food and drug interactions
leading to variable anticoagulation, and the consequent
need for relatively frequent, costly, and inconvenient blood
testing to monitor the drug’s activity. An industry of anti-
coagulant clinics in both primary and secondary care has
grown up to cater for those requiring monitoring. Despite
this, bleeding due to VKAs has remained a major cause of
iatrogenic admission to hospital.1,2 One can also argue that a
culture of fearfulness exists around patients receiving VKAs
due to the complexity of managing these patients peri-
operatively, when they are ill, or receiving new medication.
Moreover, in the current climate of concern about patient
safety, in view of the poor safety record of VKAs, would such
a drug be granted a license today?
New oral anticoagulants (NOACs) have the potential to
revolutionize the primary and secondary prevention of
thrombosis, for they have predictable pharmokinetics and
thus are given in ﬁxed doses and do not require monitoring.3
Moreover, they have minimal interactions with drugs or diet.
The prospect of a less rigid lifestyle than that required when
taking VKAs and the freeing from anticoagulation monitoring
has made NOACs very attractive to patients.
In the current issue of European Journal of Vascular and
Endovascular Surgery, Kakkos et al. present a systematic
review and meta-analysis analysing the effectiveness and
safety of NOACs compared with conventional treatment of
warfarin for treatment and secondary prevention of venous
thromboembolism (VTE).
Pooling together data from 10 randomized controlled
trials, with nearly 38,000 patients, the authors showed that
in the six trials looking at treatment of acute symptomatic
VTE, NOACs were equivalent in efﬁcacy to conventional
treatment with VKAs in reducing VTE recurrence. However,
NOACs proved to be safer than conventional treatment
because there was a signiﬁcantly reduced bleeding risk. In
fact, major bleeding rates fell from 1.73% with the use of
VKA to 1.08% with the use of NOACs.
NICE now recommend 3 months of anticoagulant treat-
ment in those with acute provoked VTE,4 and otherDOI of original article: http://dx.doi.org/10.1016/j.ejvs.2014.05.001
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10.1016/j.ejvs.2014.07.007guidelines recommend 3e6 months; but the issue of how
long to continue anticoagulation in those who have had
unprovoked VTE remains unresolved, with the trend being
to use warfarin long-term in the majority. Three secondary
prevention trials in patients with unprovoked VTE after
acute treatment compared NOAC with placebo. There was a
7.2% rate of recurrence in those receiving placebo versus
1.3% in those receiving a NOAC, at the price of an increase
in non-signiﬁcant bleeding but not major bleeding (4.3% vs.
1.8). Overall the authors concluded NOACs conferred a net
clinical beneﬁt when compared to VKAs.
Not only are NOACs attractive as regards their net clinical
beneﬁt and convenience, but a NICE Single Technology
Assessment5 and Lefebre et al.6 have evaluated the cost
efﬁcacy of rivaroxaban in the management and secondary
prevention of VTE showing that rivaroxaban is more cost-
effective (lower drug costs, fewer hospitalized days, less
bleeding) than conventional treatment of low-molecular-
weight (LMW) heparin and VKAs in the acute treatment
of VTE. Although cost-efﬁcacy is higher than VKAs in long-
term secondary use, it is still within an acceptable limit,
due to the lower bleed rates and lower intracranial hae-
morrhage rates than VKAs.7
At the time of writing, rivaroxaban and dabigatran are
the only agents to be licensed in Europe for primary and
secondary prevention of VTE, but it is expected that apix-
aban will gain a license shortly, swiftly followed by
edoxaban.
So while strong arguments of efﬁcacy, safety, cost-
efﬁcacy, and patient convenience and experience for using
NOACs in the acute management of VTE now exist, there
has been some reluctance to use them in many centres,
with concerns related to the absence of a direct reversal
agent. Antidotes are being fast tracked in development: a
direct anti-Xa agent and a direct anti-dabigatran molecule
are being trialled. But for now, unlike warfarin which can be
reversed quickly by replacing the missing Factors II, VII, IX,
and X by injection of prothrombin complex concentrates,
there is no direct antidote. However, we need to remember
that there is no reversing agent for LMW heparin and
fondaparinux either, and yet these are widely used with
fewer bleeding problems than VKAs. All the NOACs except
dabigatran are direct anti-Xa agents and thus their mecha-
nism of action is similar to LMW heparin and indeed both
have similarly short half-lives. Conceptually and pragmati-
cally it is helpful to consider that rivaroxaban, apixaban, and
edoxaban are oral forms of LMW heparin. Currently sup-
portive strategies are the mainstay of treatment of bleeding
488 EDITORIALwith both LMW heparins and NOACs, with discontinuation
of the drug, mechanical compression, surgical haemostasis
measures, and administration of transfusion support; and
because the half-life of these agents is short, they will unlike
warfarin disappear from the circulation quickly. Moreover,
warfarin reversibility while conceptually attractive was not
shown to improve outcomes in warfarin-related severe
bleeding, such as intracranial haemorrhage, suggesting that
anticoagulation reversal may not inﬂuence clinical out-
comes if bleeding occurs.8
If all supportive measures fail, then what reversal agents
are available to initiate haemostasis? The use of recombi-
nant active factor VII has had inconsistent results in clinical
settings and it is use is not clearly established.9 Dialysis can
represent an option.10 However, because more than 90% of
some NOACs (e.g. rivaroxaban) are bound to protein, it can
be considered in selected cases only. More recently, pro-
thrombin complex concentrates have been shown as po-
tential antidote to reserve the effect of rivaroxaban and
dabigatran.11 However, in reality, it is our experience, that
very few patients using these drugs routinely require an
antidote to reverse the anticoagulant effects.
Balancing the risk of clotting and the risk of bleeding still
weighs heavily on the minds of clinicians. Knowing that
evidence exists to support their effectiveness and safety for
treatment and secondary prevention of VTE will certainly
tip the scale in the favour of NOACs in their battle against
the “VKA culture”.
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